Search
Publications
Subconjunctival injection of mesenchymal stromal cells protects the cornea in an experimental model of GVHD. Martínez-Carrasco R, Sánchez-Abarca LI, Nieto-Gómez C, García EM, Sánchez-Guijo F, Argüeso P, Aijón J, Hernández-Galilea E, Velasco A. Ocul Surf. 2019 Jan 7.
Read moreSWG Educational Activities
During the annual meeting of EHA, a scientific session was organized: “Mesenchymal stromal cells: guardians of tissue homeostasis”.
Read moreSWG Educational Activities
Recruitment trialsRecruitment is underway for the following trials:
Trial on precision hematology: Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies (EXALT-2); ClinicalTrials.
Chairs and Members
Chair (2022–2025 term)Philipp Staber, Medical University Vienna (Austria)
Co-chair (2022–2025 term)Caroline Heckman, FIMM, Helsinki (Finland)
SWG Steering Committee members (2022–2025 term)
Jean-Pierre Bourquin, Universitäts-Kinderspital Zürich (Switzerland)
Kirsten Grønbæk, University of Copenhagen (Denmark)
Eva Hellström Lindberg, Karolinska Institutet, Stockholm (Sweden)
Ulrich Jäger, Medical University Vienna (Austria)
Luca Malcovati,…
Highlights from the SWG
The following activities, which were organized by EMN, also constitute contributions to and participation in the work of the EHA SWG on Multiple Myeloma.
Read moreChairs and Members
ChairPieter Sonneveld (Rotterdam, The Netherlands)
Members
Niels Abildgaard (Odense, Denmark)
Meral Beksac (Ankara, Turkey)
Luca Berthamini (Rotterdam, Netherlands)
Lenka Bešše, Brno (Czech Republic)
Dr Bila (Belgrade, Serbia)
Nicole Brolli (Milano, Italy)
Sara Bringhen (Turin, Italy)
Mario Boccadoro (Turin, Italy)
Anna Maria Brioli (Bologna, Italy)
Annemiek Broyl (Rotterdam, Netherlands)—also Chair of Young…
SWG Educational Activities
In 2021, the SWG on Multiple Myeloma contributed a major part of the ESMO-EHA guidelines for multiple myeloma. The rapid changes of the treatment landscape for this disease require an adaptation of the guidelines.
Read morePublications
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
P. Sonneveld, A. Chanan-Khan, K. Weisel, A. K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, M.
Publications
Original scientific publications
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M
Fandrei D, Huynh T, Sébert M, Aguinaga L, Bisio V, Kim R, Clappier E, Espéli M, Balabanian K, Moins-Teisserenc H, Toubert A, Dulphy N, Fenaux…
SWG Educational Activities
EHA-SWG meetingsAn EMSCO meeting was held in October 2023 (Nice, France).
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- »